Cromos Pharma is delighted to be participating again this year at the 62nd ASH Annual Meeting & Exposition 5-8 December, 2020, the premier event for malignant and non-malignant hematology. 

Extensive expertise in hematology-oncology

Cromos Pharma has extensive experience in managing all aspects of clinical trials in hematology-oncology in all Phases, I, II, III and post market/observational. Oncology studies represent nearly 20% of our work and we have successfully managed 20+ studies in hematology-oncology. Regulatory inspections and site audits attest to the highest quality of our clinical data: EMA in 2019 (1-week oncology site inspection); FDA in 2017 (2-week oncology site inspection). 

Unrivalled record for patient recruitment

We have global expertise combined with in-depth experience and knowledge in Central and Eastern Europe. We have an extensive PI/site network and unparalleled access to patient databases and key opinion leaders. These relationships have helped us achieve an unrivalled record for patient recruitment – our team has met or reduced enrollment timelines in 95% of trials conducted over our sixteen year history. Responsible recruitment is supported by our “No Patients-No Payments” initiative – a unique risk-sharing program. 

Optimized start-up timelines

Our expert team also offers the most optimized start-up timelines in these regions. For example, we routinely achieve regulatory approvals in the Republic of Georgia, within two months of project signing (In Russia, 4 months, and in Ukraine, less than 5 months).

Meet us and find out how we can support your next study 

We would like to take this opportunity to invite you to connect with us during the ASH event. Register here to join us at the event or email us at bd@cromospharma.com to set up a meeting.